Related Experiment Video
Updated: Jun 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic
Thilo Gambichler1, Marina Shtern, Sebastian Rotterdam
1Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, Bochum D-44791, Germany. t.gambichler@klinikum-bochum.de
Background:
Markers identifying premalignant and malignant melanocytic skin lesions are needed.
Objective:
We aimed to investigate the protein expression of minichromosome maintenance (MCM) proteins in melanocytic skin lesions with different malignant potential.
Methods:
Paraffin-embedded sections of benign melanocytic nevi (BN, n = 37), dysplastic nevi (DN, n = 25), and primary superficial spreading (SSM, n = 58) were assessed. Immunohistochemistry was performed for Ki-67, MCM3, MCM4, and MCM7 antibodies.
Results:
Ki-67 expression of SSM was significantly increased when compared to DN (P = .0001) and BN (P = .0015). Compared to BN and DN, expression of MCM3 was significantly increased in SSM (P < .0001 and P = .019, respectively). MCM3 expression of DN was significantly increased as compared to BN (P = .0067). There was a significant correlation between MCM3 expression and Breslow tumor thickness (r = 0.44, P = .019). In SSM, MCM4 expression was significantly increased when compared with DN (P < .0001) and BN (P = .0033). MCM4 immunoreactivity was significantly higher in DN than in BN (P = .016). Immunohistology of MCM7 did not reveal significant differences between the groups investigated (P = .48). However, immunoreactivity of MCM7 significantly correlated with Breslow tumor thickness and Clark level (r = 0.39, P = .023; r = 0.44, P = .010, respectively).
Limitations:
Limitations of our study include the absence of survival data, mRNA results, and functional studies.
Conclusions:
MCM3 as well as MCM4 are differentially expressed in BN, DN, and SSM. Hence, immunolabeling of MCM3 and MCM4 proteins appears to be a promising additive tool for distinguishing benign from malignant melanocytic skin lesions.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Microtubule Associated Proteins (MAPs)
Abnormal Proliferation
